Review Article | Published:

Review Article

Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy – an illustration with firsthand examples

Acta Pharmacologica Sinica volume 39, pages 825844 (2018) | Download Citation

Subjects

Abstract

Nanotechnology has been applied extensively in drug delivery to improve the therapeutic outcomes of various diseases. Tremendous efforts have been focused on the development of novel nanoparticles and delineation of the physicochemical properties of nanoparticles in relation to their biological fate and functions. However, in the design and evaluation of these nanotechnology-based drug delivery systems, the pharmacology of delivered drugs and the (patho-)physiology of the host have received less attention. In this review, we discuss important pharmacological mechanisms, physiological characteristics, and pathological factors that have been integrated into the design of nanotechnology-enabled drug delivery systems and therapies. Firsthand examples are presented to illustrate the principles and advantages of such integrative design strategies for cancer treatment by exploiting 1) intracellular synergistic interactions of drug-drug and drug-nanomaterial combinations to overcome multidrug-resistant cancer, 2) the blood flow direction of the circulatory system to maximize drug delivery to the tumor neovasculature and cells overexpressing integrin receptors for lung metastases, 3) endogenous lipoproteins to decorate nanocarriers and transport them across the blood-brain barrier for brain metastases, and 4) distinct pathological factors in the tumor microenvironment to develop pH- and oxidative stress-responsive hybrid manganese dioxide nanoparticles for enhanced radiotherapy. Regarding the application in diabetes management, a nanotechnology-enabled closed-loop insulin delivery system was devised to provide dynamic insulin release at a physiologically relevant time scale and glucose levels. These examples, together with other research results, suggest that utilization of the interplay of pharmacology, (patho-)physiology and nanotechnology is a facile approach to develop innovative drug delivery systems and therapies with high efficiency and translational potential.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , , , , et al. Diverse applications of nanomedicine. ACS Nano 2017; 11: 2313–81.

  2. 2.

    , . Impact of nanotechnology on drug delivery. ACS Nano 2009; 3: 16–20.

  3. 3.

    , , , , , . Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks. Nanoscale 2017; 9: 1334–55.

  4. 4.

    . Strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery. Expert Opin Drug Deliv 2016; 13: 609–12.

  5. 5.

    , , , . Cancer nanomedicine: Progress, challenges and opportunities. Nat Rev Cancer 2017; 17: 20–37.

  6. 6.

    , , , , . Nanomedicine of synergistic drug combinations for cancer therapy - strategies and perspectives. J Control Release 2016; 240: 489–503.

  7. 7.

    , , , , , . Recent progress in microrna delivery for cancer therapy by non-viral synthetic vectors. Adv Drug Deliv Rev 2015; 81: 142–60.

  8. 8.

    , , , , . Emerging micro- and nanotechnology based synthetic approaches for insulin delivery. Chem Soc Rev 2014; 43: 3595–629.

  9. 9.

    , . Nanosensors and nanomaterials for monitoring glucose in diabetes. Trends Mol Med 2010; 16: 584–93.

  10. 10.

    . Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010; 37: 48–57.

  11. 11.

    , . Nanotechnology - novel therapeutics for CNS disorders. Nat Rev Neurol 2012; 8: 307–18.

  12. 12.

    , , , , , , et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater 2016; 1: 1–12.

  13. 13.

    , , , , , . Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev 2017; 108: 25–38.

  14. 14.

    , , , . Challenges of clinical translation in nanomedicine: A qualitative study. Nanomedicine 2016; 12: 893–900.

  15. 15.

    . Toward a full understanding of the epr effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 2015; 91: 3–6.

  16. 16.

    , . Intra-tumor heterogeneity of cancer cells and its implications for cancer treatment. Acta Pharmacol Sin 2015; 36: 1219–27.

  17. 17.

    , , . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015; 33: 941–51.

  18. 18.

    , . Design considerations for nanotherapeutics in oncology. Nanomedicine 2015; 11: 1893–907.

  19. 19.

    , , , , . Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000; 65: 271–84.

  20. 20.

    , . A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387–92.

  21. 21.

    , , , , , . A novel solid lipid nanoparticle formulation for active targeting to tumor alpha(v) beta(3) integrin receptors reveals cyclic rgd as a double-edged sword. Adv Healthc Mater 2012; 1: 600–8.

  22. 22.

    , , , , , , et al. Hybrid quantum dot-fatty ester stealth nanoparticles: Toward clinically relevant in vivo optical imaging of deep tissue. ACS Nano 2011; 5: 1958–66.

  23. 23.

    , , , , . Future of nanotherapeutics: Targeting the cellular sub-organelles. Biomaterials 2016; 97: 10–21.

  24. 24.

    , , , . Intracellular drug release nanosystems. Mater Today 2012; 15: 436–42.

  25. 25.

    , , , , , , et al. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model. Mol Pharm 2014; 11: 2659–74.

  26. 26.

    , , , . Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 2005; 11: 6944–9.

  27. 27.

    , , . Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clin Pharmacokinet 2003; 42: 419–36.

  28. 28.

    , , , , , , et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (Caelyx®/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440–9.

  29. 29.

    , , . To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010; 148: 135–46.

  30. 30.

    , , , , , , et al. Acidity-triggered ligand-presenting nanoparticles to overcome sequential drug delivery barriers to tumors. Nano Lett 2017; 17: 5429–36.

  31. 31.

    , , , . Cancer drug resistance: An evolving paradigm. Nat Rev Cancer 2013; 13: 714–26.

  32. 32.

    , , , , . Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 2007; 59: 491–504.

  33. 33.

    , , , . Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441–54.

  34. 34.

    , . Different strategies to overcome multidrug resistance in cancer. Biotechnol Adv 2013; 31: 1397–407.

  35. 35.

    . Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006; 580: 2903–9.

  36. 36.

    , , , , , , et al. Polymer-lipid hybrid nanoparticles synchronize pharmacokinetics of co-encapsulated doxorubicin-mitomycin C and enable their spatiotemporal co-delivery and local bioavailability in breast tumor. Nanomedicine 2016; 12: 1279–90.

  37. 37.

    , , , , . Doxorubicin and mitomycin c co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts. Cancer Lett 2013; 334: 263–73.

  38. 38.

    , , , , . A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. Drug Deliv Transl Res 2012; 2: 95–105.

  39. 39.

    , , , . In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model. Eur J Pharm Biopharm 2007; 65: 300–8.

  40. 40.

    , , , , , , et al. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells. Pharm Res 2006; 23: 1574–85.

  41. 41.

    , , , , , . A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 2006; 317: 1372–81.

  42. 42.

    , , , . Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer. J Control Release 2006; 116: 275–84.

  43. 43.

    . , . Combination Chemotherapy in Cancer: Principles, Evaluation and Drug Delivery Strategies. In: Özdemir Ö, editor. Current Cancer Treatment - Novel Beyond Conventional Approaches. InTech; 2011. p 693–714.

  44. 44.

    , , , , , . Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009; (2): CD003372.

  45. 45.

    , , , , , , et al. Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers. Curr Cancer Drug Targets 2006; 6: 455–89.

  46. 46.

    , , , , , . A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs. Mol Pharm 2011; 8: 1257–65.

  47. 47.

    , , , , , . Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(d, l-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin. J Control Release 2012; 163: 93–9.

  48. 48.

    , , . , , , et al. Safety, pharmacokinetics, and efficacy of cpx-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 692–700.

  49. 49.

    , , , , , , et al. First-in-man study of cpx-351: A liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol 2011; 29: 979–85.

  50. 50.

    , , , , , . Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol Res 2007; 16: 361–74.

  51. 51.

    , , , , , , et al. Ratiometric dosing of anticancer drug combinations: Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 2006; 5: 1854–63.

  52. 52.

    , , , , , , et al. Albumin biomimetic nanocorona improves tumor targeting and penetration for synergistic therapy of metastatic breast cancer. Adv Funct Mater 2017; 27: 1605679–93.

  53. 53.

    , , , , , . Antitumor activity of Triolimus: A novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther 2012; 11: 2233–42.

  54. 54.

    US Food & Drug Administration. Updated 2017 Aug 4; cited 2018 Jan 08. FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia. Available from:

  55. 55.

    US National Library of Medicine. Updated 2017 Nov 21; cited 2018 Jan 08. Pharmaceuticals J. Phase III study of CPX-351 versus 7+3 in patients 60-75 years old with untreated high risk (secondary) acute myeloid leukemia (301). Available from:

  56. 56.

    . Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 2001; 8: 739–61.

  57. 57.

    , , . Bioreductive therapies: An overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 1998; 42: 755–62.

  58. 58.

    , , . Preferential activation of mitomycin c to cytotoxic metabolites by hypoxic tumor cells. Cancer Res 1980; 40: 2356–60.

  59. 59.

    , . Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400: 139–54.

  60. 60.

    , , , , , . Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466–8.

  61. 61.

    , , , , . Quinone methide derivatives: Important intermediates to DNA alkylating and DNA cross-linking actions. Curr Med Chem 2005; 12: 2893–913.

  62. 62.

    . Mitomycin: Its evolving role in the treatment of breast cancer. Oncology 1993; 50: 1–8.

  63. 63.

    , , , . Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: A randomized study. Cancer Treat Rep 1986; 70: 1181–6.

  64. 64.

    , , , , , , et al. Sample extraction and simultaneous chromatographic quantitation of doxorubicin and mitomycin C following drug combination delivery in nanoparticles to tumor-bearing mice. J Vis Exp 2017; 128: e56159–70.

  65. 65.

    , , , , , . A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res Treat 2010; 119: 255–69.

  66. 66.

    , , , . On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells. Drug Metabol Drug Interact 2007; 22: 201–33.

  67. 67.

    , , , , . In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin. Eur J Pharm Biopharm 2006; 62: 321–31.

  68. 68.

    , , . In vivo efficacy and toxicity of intratumorally delivered mitomycin c and its combination with doxorubicin using microsphere formulations. Anticancer Drugs 2005; 16: 423–33.

  69. 69.

    , , . Differential properties of cisplatin and tetraplatin with respect to cytotoxicity and perturbation of cellular glutathione levels. Cancer Chemother Pharmacol 1991; 28: 273–6.

  70. 70.

    , , . Physical principles of nanoparticle cellular endocytosis. ACS Nano 2015; 9: 8655–71.

  71. 71.

    , , , , , . Drug resistance in breast cancer cells: Biophysical characterization of and doxorubicin interactions with membrane lipids. Mol Pharm 2010; 7: 2334–48.

  72. 72.

    , , , , . Biomechanics and thermodynamics of nanoparticle interactions with plasma and endosomal membrane lipids in cellular uptake and endosomal escape. Langmuir 2014; 30: 7522–32.

  73. 73.

    , , . Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles. Adv Drug Deliv Rev 2013; 65: 1686–98.

  74. 74.

    , , , , , , et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci U S A 2010; 107: 7449–54.

  75. 75.

    , , , , , , et al. The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells. Nat Commun 2017; 8: 864–78.

  76. 76.

    , , , , , , et al. Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res 2014; 74: 4976–82

  77. 77.

    . Cholesterol forges link between obesity and breast cancer. Science 2013; 342: 1028.

  78. 78.

    , , , , , , et al. Coordinating biointeraction and bioreaction of a nanocarrier material and an anticancer drug to overcome membrane rigidity and target mitochondria in multidrug-resistant cancer cells. Adv Funct Mater 2017: 1700804–16.

  79. 79.

    , . Docosahexaenoic acid: Membrane properties of a unique fatty acid. Chem Phys Lipids 2003; 126: 1–27.

  80. 80.

    , , , , , . Dietary omega-3 polyunsaturated fatty acid DHA: A potential adjuvant in the treatment of cancer. Biomed Res Int 2013; 2013: 310186–97.

  81. 81.

    . Targeting metastasis. Nat Rev Cancer 2016; 16: 201–18.

  82. 82.

    . Cancer metastases: Challenges and opportunities. Acta Pharm Sin B 2015; 5: 402–18.

  83. 83.

    Cancer Research UK. Updated 2016 Apr 30; cited 2018 Jan 08. Radiotherapy side effects. Available from:

  84. 84.

    , , . Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275–84.

  85. 85.

    , . Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011; 153: 198–205.

  86. 86.

    , , , . Emerging nanomedicine approaches fighting tumor metastasis: Animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy. Chem Soc Rev 2016; 45: 6250–69.

  87. 87.

    , , , , , , , et al. Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2012; 12: 39–50.

  88. 88.

    , , . Targeting tumor metastases: Drug delivery mechanisms and technologies. J Control Release 2015; 219: 215–23.

  89. 89.

    , , , , . Atypical pulmonary metastases: Spectrum of radiologic findings. Radiographics 2001; 21: 403–17.

  90. 90.

    , , , , , . The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: A seer based study. Oncotarget 2017; 8: 26368–79.

  91. 91.

    , , , , , , et al. Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997; 113: 37–49.

  92. 92.

    , , , , . Metastatic patterns of breast cancer subtypes: What radiologists should know in the era of personalized cancer medicine. Clin Radiol 2015; 70: 1–10.

  93. 93.

    , . Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10: 9–22.

  94. 94.

    , . Function and antagonism of beta3 integrins in the development of cancer therapy. Curr Cancer Drug Targets 2009; 9: 519–40.

  95. 95.

    , , . Rgd-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012; 9: 2961–73.

  96. 96.

    , , , , , , et al. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of alpha(v)beta(3) integrin-overexpressing breast cancer cells. Drug Deliv Transl Res 2015; 5: 15–26.

  97. 97.

    , . Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 2006; 307: 93–102.

  98. 98.

    , , , , , , et al. Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. Acta Pharmacol Sin 2017; 38: 835–47.

  99. 99.

    , , . , , , et al. Human endothelial cells express integrin receptors on the luminal aspect of their membrane. Blood 1992; 80: 437–46.

  100. 100.

    , , , , , . Integrins in human cells and tumors. Cell Differ Dev 1990; 32: 215–27.

  101. 101.

    , , . Regulated expression of integrins and other adhesion molecules during differentiation of monocytes into macrophages. Cell Immunol 1994; 156: 191–211.

  102. 102.

    , , , , . The shifting landscape of metastatic breast cancer to the CNS. Neurosurg Rev 2013; 36: 377–82.

  103. 103.

    , , , , . Breast cancer brain metastases: Biology and new clinical perspectives. Breast Cancer Res 2016; 18: 8–17.

  104. 104.

    , . Nanomedicines for the treatment of CNS diseases. J Neuroimmune Pharmacol 2017; 12: 1–5.

  105. 105.

    , , . Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev 2012; 64: 686–700.

  106. 106.

    , , , , , . Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 2016; 235: 34–47.

  107. 107.

    . From blood-brain barrier to blood-brain interface: New opportunities for CNS drug delivery. Nat Rev Drug Discov 2016; 15: 275–92.

  108. 108.

    . Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012; 32: 1959–72.

  109. 109.

    , . Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012; 503: 269–92.

  110. 110.

    . Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 2016; 6: 268–86.

  111. 111.

    , , . Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther Deliv 2013; 4: 629–40.

  112. 112.

    , , , , , , et al. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials 2015; 37: 425–35.

  113. 113.

    , , , , , , et al. High transcytosis of melanotransferrin (p97) across the blood-brain barrier. J Neurochem 2002; 83: 924–33.

  114. 114.

    , , , , , , et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 2008; 324: 1064–72.

  115. 115.

    , , , , , , et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006; 317: 1246–53.

  116. 116.

    , , , , , , et al. Comparison of five peptide vectors for improved brain delivery of the lysosomal enzyme arylsulfatase A. J Neurosci 2014; 34: 3122–9.

  117. 117.

    . Blood-brain barrier drug delivery of igg fusion proteins with a transferrin receptor monoclonal antibody. Expert Opin Drug Deliv 2015; 12: 207–22.

  118. 118.

    , , , . The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the cdr regions. MAbs 2010; 2: 256–65.

  119. 119.

    , , . Nanotechnological advances for the delivery of cns therapeutics. Adv Drug Deliv Rev 2012; 64: 686–700.

  120. 120.

    , , , , , , et al. A new method for evaluating actual drug release kinetics of nanoparticles inside dialysis devices via numerical deconvolution. J Control Release 2016; 243: 11–20.

  121. 121.

    , , , , , , et al. Blood–brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano 2016; 10: 9999–10012.

  122. 122.

    , , , , , , et al. PH-dependent doxorubicin release from terpolymer of starch, polymethacrylic acid and polysorbate 80 nanoparticles for overcoming multi-drug resistance in human breast cancer cells. Eur J Pharm Biopharm 2012; 82: 587–97.

  123. 123.

    , , , , , , et al. Design of ph-responsive nanoparticles of terpolymer of poly(methacrylic acid), polysorbate 80 and starch for delivery of doxorubicin. Colloids Surf B Biointerfaces 2013; 101: 405–13.

  124. 124.

    , , , , . Multifunctional terpolymeric mri contrast agent with superior signal enhancement in blood and tumor. J Control Release 2013; 167: 11–20.

  125. 125.

    . Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB). J Microencapsul 2013; 30: 49–54.

  126. 126.

    , , , , , , et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res 2003; 20: 409–16.

  127. 127.

    , , , , , , et al. Uptake mechanism of ApoE-modified nanoparticles on brain capillary endothelial cells as a blood-brain barrier model. PLoS One 2012; 7: e32568–75.

  128. 128.

    , , , , , , et al. A multifunctional polymeric nanotheranostic system delivers doxorubicin and imaging agents across the blood-brain barrier targeting brain metastases of breast cancer. ACS Nano 2014; 8: 9925–40.

  129. 129.

    , , , , . Evaluation of new bi-functional terpolymeric nanoparticles for simultaneous in vivo optical imaging and chemotherapy of breast cancer. Drug Deliv Transl Res 2012; 2: 437–53.

  130. 130.

    , , , , , , et al. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer. J Control Release 2017; 246: 98–109.

  131. 131.

    , , , , , , et al. Two-step targeted hybrid nanoconstructs increase brain penetraion and efficacy of the therapeutic anitbody trastuzumab against brain metastasis of Her2 positive breast cancer. Adv Funct Mater 2018; 28: 1705668.

  132. 132.

    . Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705–13.

  133. 133.

    , . Tumor hypoxia: Definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93: 266–76.

  134. 134.

    , . Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy. Pharmacol Res 2017; 126: 97–108.

  135. 135.

    , , . Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer 2017; 17: 457–75.

  136. 136.

    , , , . The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence. Nat Rev Cancer 2015; 15: 409–25.

  137. 137.

    , , , , . Hypoxia and radiation therapy: Past history, ongoing research, and future promise. Curr Mol Med 2009; 9: 442–58.

  138. 138.

    , , editors. Radiobiology for the radiologist. Lippincott Williams & Wilkins; 2006.

  139. 139.

    . Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 2004; 5: 405–6.

  140. 140.

    , . Hypoxia inducible factor-1α as a cancer drug target. Mol Cancer Ther 2004; 3: 647–54.

  141. 141.

    , , . Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85–95.

  142. 142.

    . The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9: 10–7.

  143. 143.

    , . Hypoxia, inflammation, and the tumor microenvironment in metastatic disease. Cancer Metastasis Rev 2010; 29: 285–93.

  144. 144.

    . Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625–34.

  145. 145.

    , , , , , , et al. Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. Microvasc Res 2009; 77: 96–103.

  146. 146.

    , , , , , , et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004; 96: 946–56.

  147. 147.

    , , . Carbonic anhydrase ix: Regulation and role in cancer. Subcell Biochem 2014; 75: 199–219.

  148. 148.

    . Oxygen sensing, homeostasis, and disease. N Engl J Med 2011; 365: 537–47.

  149. 149.

    , , , . Hypoxia and mitochondrial oxidative metabolism. Biochim Biophys Acta 2010; 1797: 1171–7.

  150. 150.

    , . Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4: 891.

  151. 151.

    , , . Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J Cell Mol Med 2010; 14: 771–94.

  152. 152.

    , , , , , , et al. Design of hybrid MnO2-polymer-lipid nanoparticles with tunable oxygen generation rates and tumor accumulation for cancer treatment. Adv Funct Mater 2015; 25: 1858–72.

  153. 153.

    , . A new life to an old material. Materialstoday. 2015 Mar 5 (cited 2018 Jan 08); Available from:

  154. 154.

    , , , , , , et al. Multifunctional albumin- MnO2nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response. ACS Nano 2014; 8: 3202–12.

  155. 155.

    , , , , , , et al. Hybrid manganese dioxide nanoparticles potentiate radiation therapy by modulating tumor hypoxia. Cancer Res 2016; 76: 6643–56.

  156. 156.

    , , , , , , et al. Tumor microenvironment-modulating nanoparticles boost chemotherapy efficacy and anti-tumor immunity. Annual meeting of American Association of Pharmaceutical Sciences; 2017 Nov 12-15; San Diego, CA, USA.; Poster ID:M4058.

  157. 157.

    World Health Organization. 10 facts on diabetes. Updated 2016 Apr; cited 2018 Jan 08. Available from:

  158. 158.

    . The pathogenesis and natural history of type 1 diabetes. Cold Spring Harb Perspect Med 2012; 2: a007641–59.

  159. 159.

    , , . Genetics, pathogenesis and clinical interventions in type[thinsp]1 diabetes. Nature 2010; 464: 1293–300.

  160. 160.

    , , , , , . Acute effects on insulin sensitivity and diurnal metabolic profiles of a high-sucrose compared with a high-starch diet. Am J Clin Nutr 1998; 67: 1186–96.

  161. 161.

    Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31: S55–60.

  162. 162.

    , , , , , , editors. Pharmacotherapy: A pathophysiologic approach. 8th edition. McGraw-Hill Education; 2011.

  163. 163.

    . Diabetes mellitus: Type 1 and type 2. In: Stang J, Story M, editors. Guide-lines for Adolescent Nutrition Services. 2005: p 167-82. Available from:

  164. 164.

    , , , . Pharmacotherapy in type 1 diabetes. Can J Diabetes 2013; 37: S56–60.

  165. 165.

    , , . Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol Rev 2011; 91: 79–118.

  166. 166.

    , , , , , . Continuous subcutaneous insulin infusion in diabetes: Patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev 2016; 32: 21–39.

  167. 167.

    , . Insulin infusion set: The achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol 2012; 6: 954–64.

  168. 168.

    , , , , , , et al. Nanotechnology-enabled closed loop insulin delivery device: In vitro and in vivo evaluation of glucose-regulated insulin release for diabetes control. Adv Funct Mater 2011; 21: 73–82.

  169. 169.

    , , , , , , et al. Microfabricated microporous membranes reduce the host immune response and prolong the functional lifetime of a closed-loop insulin delivery implant in a type 1 diabetic rat model. Biomaterials 2015; 47: 51–61.

  170. 170.

    , , , , , , et al. In vitro and in vivo testing of glucose-responsive insulin-delivery microdevices in diabetic rats. Lab Chip 2012; 12: 2533–9.

  171. 171.

    , , , , , , et al. In vivo performance and biocompatibility of a subcutaneous implant for real-time glucose-responsive insulin delivery. Diabetes Technol Ther 2015; 17: 255–67.

  172. 172.

    , , . Glucose-responsive bioinorganic nanohybrid membrane for self-regulated insulin release. Adv Funct Mater 2010; 20: 1404–12.

  173. 173.

    , , , , , , et al. Enhancing thermal stability of a highly concentrated insulin formulation with pluronic F-127 for long-term use in microfabricated implantable devices. Drug Deliv Transl Res 2017; 7: 529–43.

  174. 174.

    , . Modulated insulin permeation across a glucose-sensitive polymeric composite membrane. J Control Release 2002; 80: 169–78.

  175. 175.

    , , , , , . Characterization of nanostructure of stimuli-responsive polymeric composite membranes. Biomacromolecules 2004; 5: 1248–55.

  176. 176.

    , . Temperature and ph-responsive polymeric composite membranes for controlled delivery of proteins and peptides. Biomaterials 2004; 25: 5281–91.

  177. 177.

    . Synthesis, equilibrium swelling, kinetics, permeability and applications of environmentally responsive gels. In: Dušek K, editor. Responsive gels: Volume transitions II. Springer Berlin Heidelberg, Berlin, Heidelberg; 1993. p 81–144.

  178. 178.

    . , . Dynamic behavior of glucose oxidase-containing microparticles of poly(ethylene glycol)-grafted cationic hydrogels in an environment of changing pH. Biomaterials 2000; 21: 1439–50.

  179. 179.

    , , , , , , et al. Nanotechnology-enabled closed loop insulin delivery device: In vitro and in vivo evaluation of glucose-regulated insulin release for diabetes control. Adv Funct Mater 2011; 21: 73–82.

  180. 180.

    , , , , . Pegylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev 2016; 99: 28–51.

  181. 181.

    . Albumin-bound paclitaxel: A next-generation taxane. Expert Opin Pharmacother 2006; 7: 1041–53.

  182. 182.

    . Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment. South Asian J Cancer 2015; 4: 38–40.

  183. 183.

    . Species similarities and differences in pharmacokinetics. Drug Metab Dispos 1995; 23:1008–21.

  184. 184.

    , , , , , , et al. Organ-on-a-chip platforms for studying drug delivery systems. J Control Release 2014; 190: 82–93.

  185. 185.

    , , , , , , et al. Mechanism of hard-nanomaterial clearance by the liver. Nat Mater 2016; 15: 1212–21.

  186. 186.

    , , , , , , et al. Inhibition of kupffer cell autophagy abrogates nanoparticle-induced liver injury. Adv Healthc Mater 2017; 6. doi: 10.1002/adhm.201601252.

  187. 187.

    , , , , , , et al. Kupffer cells are central in the removal of nanoparticles from the organism. Part Fibre Toxicol 2007; 4: 10–7.

  188. 188.

    , , , , , , et al. Effective delivery of chemotherapeutic nanoparticles by depleting host kupffer cells. Int J Cancer 2012; 131: 2402–10.

  189. 189.

    , , , , , , et al. Intra and inter-molecular interactions dictate the aggregation state of irinotecan co-encapsulated with floxuridine inside liposomes. Pharm Res 2008; 25: 1702–13.

  190. 190.

    , , , , . Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles. J Control Release 2008; 128: 60–70.

  191. 191.

    , , , . Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN). Pharm Res 2006; 23: 1877–87.

Download references

Acknowledgements

This work is supported in part by the Canadian Breast Cancer Foundation (CBCF) – Ontario region, the Canadian Institutes of Health Research (CIHR), the National Science and Engineering Research Council (NSERC) of Canada, the Juvenile Diabetes Research Foundation (JDRF)-Lily, and the University of Toronto Connaught Innovation Award to Xiao Yu WU. University of Toronto open scholarships to Tian ZHANG, Brian LU, Mohammad A AMINI, and HoYin LIP and a University of Toronto Connaught International Scholarship for Doctoral Students to Taksim AHMED are also acknowledged.

Author information

Affiliations

  1. Advanced Pharmaceutics & Drug Delivery Laboratory, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

    • Rui Xue Zhang
    • , Jason Li
    • , Tian Zhang
    • , Mohammad A Amini
    • , Chunsheng He
    • , Brian Lu
    • , Taksim Ahmed
    • , HoYin Lip
    •  & Xiao Yu Wu
  2. School of Life Sciences, Northwestern Polytechnical University, Xi'an, China

    • Rui Xue Zhang
  3. Departments of Medical Biophysics and Radiation Oncology, University of Toronto, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

    • Andrew M Rauth

Authors

  1. Search for Rui Xue Zhang in:

  2. Search for Jason Li in:

  3. Search for Tian Zhang in:

  4. Search for Mohammad A Amini in:

  5. Search for Chunsheng He in:

  6. Search for Brian Lu in:

  7. Search for Taksim Ahmed in:

  8. Search for HoYin Lip in:

  9. Search for Andrew M Rauth in:

  10. Search for Xiao Yu Wu in:

Corresponding author

Correspondence to Xiao Yu Wu.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/aps.2018.33